Streetbeat News

AZNCF

Astrazeneca plc

https://www.astrazeneca.com/home

CEO

Pascal Soriot

Employees

83,100

Industry

Pharmaceutical Preparation Manufacturing

Open

155.00

Mkt cap

240B

Volume

100

High

155.00

P/E Ratio

34.44

52-wk high

175.00

Low

155.00

Div yield

0.01

52-wk low

120.64

AstraZeneca's Q2 FY23 earnings beat consensus with a core EPS of $2.15, up 25% Y/Y, despite no COVID-19 vaccine sales. The strong performance of its cancer drugs offset the loss of vaccine sales. Total revenue was $11.4 billion, up 6%, beating analyst estimates. AstraZeneca's unit Alexion has agreed to buy Pfizer's preclinical gene therapy programs for up to $1 billion. The deal is expected to close in Q3.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 12:46 pm

Ionis Pharmaceuticals has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize Eplontersen in Latin America. The two companies will continue to jointly develop and commercialize Eplontersen in the U.S.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 11:08 am

Alexion, a subsidiary of AstraZeneca, has agreed to purchase and license a portfolio of preclinical gene therapy programs from Pfizer for a total consideration of up to $1B, plus tiered royalties on sales.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 7:35 am

AstraZeneca's drug Soliris (Eculizumab) has received approval in the European Union for expanded use to include the treatment of refractory generalized myasthenia gravis in children and adolescents.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 8:15 am

The FDA has approved AstraZeneca and Sanofi's Beyfortus for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The approval covers children up to 24 months of age. Beyfortus was approved in the EU in November 2022 and applications are under review in China, Japan, and other countries. The drug will be available in the US before the 2023-2024 RSV season.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:07 pm

AstraZeneca reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with advanced or metastatic non-small cell lung cancer. The drug showed a statistically significant improvement for progression-free survival compared to the current standard of care chemotherapy. However, some adverse events were observed, including some Grade 5 events (Death related to AE), which may be causing investor concern. The drug is jointly developed by AstraZeneca and Daiichi Sankyo.

Portfolio Pulse from Vandana Singh

July 03, 2023 | 9:50 am

AstraZeneca has released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi plus Imjudo in unresectable hepatocellular carcinoma patients. The data shows that the treatment reduced the risk of death by 22% compared to Bayer's Nexavar. The safety profile was consistent with known profiles and no new safety signals were observed. AstraZeneca's shares are down 0.16% at $70.85.

Portfolio Pulse from Vandana Singh

June 29, 2023 | 5:41 pm

The European Union has recommended AstraZeneca's Soliris for marketing authorization for expanded use in refractory generalized myasthenia gravis (gMG) in children and adolescents. If approved, Soliris would be the first targeted therapy for pediatric patients with refractory gMG in the EU.

Portfolio Pulse from Vandana Singh

June 26, 2023 | 12:29 pm

Pieris Pharmaceuticals announced that partner AstraZeneca has decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an asthma drug, due to lung findings from a non-clinical toxicology study. Pieris will review the implications of the data and AstraZeneca's decision on the program.

Portfolio Pulse from Vandana Singh

June 21, 2023 | 1:41 pm

AstraZeneca is reportedly considering spinning off its China business and listing a separate unit in Hong Kong amid geopolitical tensions. China accounted for 13% of the company's overall sales in 2022. The spin-off could protect AstraZeneca from tensions while retaining business control.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 12:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.